Franklin Genomic Advancements ETF (BATS:HELX – Get Free Report) was the recipient of a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 367 shares, a drop of 82.1% from the September 15th total of 2,051 shares. Based on an average trading volume of 11,494 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.1% of the shares of the company are sold short.
Franklin Genomic Advancements ETF Stock Up 1.9%
Franklin Genomic Advancements ETF stock traded up $0.79 during mid-day trading on Friday, hitting $42.64. 131,015 shares of the company’s stock traded hands, compared to its average volume of 2,917. Franklin Genomic Advancements ETF has a one year low of $31.24 and a one year high of $45.58. The firm has a 50 day moving average price of $42.26 and a 200 day moving average price of $38.03. The company has a market cap of $17.06 million, a PE ratio of 26.71 and a beta of 1.05.
About Franklin Genomic Advancements ETF
Featured Stories
- Five stocks we like better than Franklin Genomic Advancements ETF
- 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
- Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
- Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
Receive News & Ratings for Franklin Genomic Advancements ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Franklin Genomic Advancements ETF and related companies with MarketBeat.com's FREE daily email newsletter.
